Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EQUINOX: EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
NCT07795814Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF). Started Aug 2026; status: recruiting.
02
Drugs
EDG-15400
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07795814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07795814.